Twitter_125

News : Latest News, Press Releases & Events

Your email address will not be published. Required fields are marked *

SPX-101 is Stable In and Retains Function After Exposure to Cystic Fibrosis Sputum July 18, 2018
Phase 2 Study Shows Promising Results for Potential Mucus Clearance Drug June 8, 2018
Spyryx SPX-101 Phase 2 HOPE-1 Trial Shows Improvement in Lung Function in Patients with Cystic Fibrosis via Novel Modulation of ENaC June 6, 2018
Data from Spyryx Biosciences’ HOPE-1 Phase 2 Clinical Trial to be Presented in a Late-Breaking Oral Presentation at the 41st European Cystic Fibrosis Conference May 8, 2018
Spyryx Biosciences Expands with Election of Roger Jeffs, PhD as Independent Director January 16, 2018
Positive Pre-Clinical Data Supporting SPX-101 to be Presented at the North American Cystic Fibrosis Conference November 1, 2017